- Home
- SCYX vs TRAW Comparison
SCYX vs TRAW Comparison
Compare SCYX & TRAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCYX
- TRAW
- Stock Information
- Founded
- SCYX 1999
- TRAW 1998
- Country
- SCYX United States
- TRAW United States
- Employees
- SCYX N/A
- TRAW N/A
- Industry
- SCYX Biotechnology: Pharmaceutical Preparations
- TRAW
- Sector
- SCYX Health Care
- TRAW
- Exchange
- SCYX Nasdaq
- TRAW NYSE
- Market Cap
- SCYX 41.0M
- TRAW 38.0M
- IPO Year
- SCYX 2014
- TRAW 2013
- Fundamental
- Price
- SCYX $1.09
- TRAW $7.70
- Analyst Decision
- SCYX Buy
- TRAW
- Analyst Count
- SCYX 1
- TRAW 0
- Target Price
- SCYX N/A
- TRAW N/A
- AVG Volume (30 Days)
- SCYX 214.8K
- TRAW 118.7K
- Earning Date
- SCYX 03-27-2025
- TRAW 03-31-2025
- Dividend Yield
- SCYX N/A
- TRAW N/A
- EPS Growth
- SCYX N/A
- TRAW N/A
- EPS
- SCYX N/A
- TRAW N/A
- Revenue
- SCYX $8,566,000.00
- TRAW $226,000.00
- Revenue This Year
- SCYX N/A
- TRAW $3.81
- Revenue Next Year
- SCYX $365.06
- TRAW N/A
- P/E Ratio
- SCYX N/A
- TRAW N/A
- Revenue Growth
- SCYX N/A
- TRAW N/A
- 52 Week Low
- SCYX $0.90
- TRAW $4.06
- 52 Week High
- SCYX $3.07
- TRAW $27.50
- Technical
- Relative Strength Index (RSI)
- SCYX 46.40
- TRAW 50.05
- Support Level
- SCYX $1.02
- TRAW $6.86
- Resistance Level
- SCYX $1.13
- TRAW $7.66
- Average True Range (ATR)
- SCYX 0.07
- TRAW 0.62
- MACD
- SCYX 0.00
- TRAW 0.01
- Stochastic Oscillator
- SCYX 44.44
- TRAW 77.03
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About TRAW TRAWS PHARMA INC
Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.